Rapid proteomic analysis for solid tumors reveals LSD1 as a drug target in an end-stage cancer patient

Research output: Contribution to journalJournal articleResearchpeer-review

Recent advances in mass spectrometry (MS)-based technologies are now set to transform translational cancer proteomics from an idea to a practice. Here, we present a robust proteomic workflow for the analysis of clinically relevant human cancer tissues that allows quantitation of thousands of tumor proteins in several hours of measuring time and a total turnaround of a few days. We applied it to a chemorefractory metastatic case of the extremely rare urachal carcinoma. Quantitative comparison of lung metastases and surrounding tissue revealed several significantly upregulated proteins, among them lysine-specific histone demethylase 1 (LSD1/KDM1A). LSD1 is an epigenetic regulator and the target of active development efforts in oncology. Thus, clinical cancer proteomics can rapidly and efficiently identify actionable therapeutic options. While currently described for a single case study, we envision that it can be applied broadly to other patients in a similar condition.

Original languageEnglish
JournalMolecular Oncology
Issue number8
Pages (from-to)1296-1307
Number of pages12
Publication statusPublished - 2018

    Research areas

  • case study, clinical proteomics, epigenetics, mass spectrometry, urachal carcinoma

Number of downloads are based on statistics from Google Scholar and www.ku.dk

No data available

ID: 198265634